Dr. Richard Isaacson was featured in The Wall Street Journal discussing the growing role of FDA-cleared blood tests in the diagnosis of Alzheimer’s disease. The article explores how new blood-based biomarkers, including tau and beta-amyloid proteins, are helping simplify the diagnostic process and expand access to earlier detection.

Read the full Wall Street Journal article to learn more about the latest advances in Alzheimer’s blood testing and diagnosis.